Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management
Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management
This study involves an evaluation of whether providing small financial incentives weekly for
 dietary self-monitoring and/or weight loss improves short- and long-term weight loss.
All participants will participate in an 18-month weight management program delivered via
 videoconference. They will be randomized to receive adjunctive financial incentives for
 dietary self-monitoring, weight loss, both, or neither. The study will be conducted in three
 phases: Phase I (months 1-6) involves weight loss with incentives; Phase II (months 7-12)
 involves weight loss maintenance with incentives; and Phase III (months 13-18) involves
 weight loss maintenance without incentives.
Inclusion Criteria:

 -  BMI ≥30 kg/m2

 -  Desire to lose weight

 -  Agrees to attend visits per protocol

 -  Access to telephone and reliable transportation

 -  Able to stand for weight measurements without assistance

 -  Able to speak and read English

 -  Possess smart phone with data and texting plan

 -  Possess e-mail address

 -  Able to use a smartphone, tablet or computer with a video camera or webcam and
 microphone to download apps and to connect to a video conference call without
 assistance

 -  Score of at least 4 out of 6 on a validated cognitive screener

 Exclusion Criteria:

 -  Weight >380 lb

 -  Weight loss of at least 5 lbs in the month prior to screening

 -  Currently enrolled or enrollment in previous month in a weight loss program

 -  Current use of weight loss medication

 -  History of bariatric surgery or planning to have bariatric surgery in the study
 timeframe

 -  Residing in a nursing home or receiving home health care

 -  Impaired hearing

 -  Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g.,
 schizophrenia, psychosis)

 -  Current treatment for cancer or being treated for cancer (besides non-melanoma skin
 cancer) in the last 6 months

 -  Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia

 -  Pregnant, breastfeeding, or planning to become pregnant within the study timeframe

 -  Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40
 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone

 -  Chronic kidney disease at stage 4 or 5

 -  Unstable heart disease in the 6 months prior to screening

 -  Exertional chest pain or dyspnea

 -  History of ascites requiring paracentesis

 -  Pain or other condition that prohibits mild/moderate exercise